Last updated: 11/07/2018 09:38:54
U0289-405: An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of the Acne System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%) in Subjects with Acne
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of the Acne System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%) in Subjects with Acne
Trial description: This study is being conducted to obtain safety, efficacy, and satisfaction data on the combination of topical Benzoyl Peroxide (BPO) 2.5% and the topical keratolytic agent Salicylic Acid (SA) 0.5% in the treatment of moderate to severe acne. Subjects with moderate or severe acne will be asked to apply the commercially available, over-the-counter products Foam Deep Cleanser (2.5% BPO), Foam Advanced Acne Treatment (2.5% BPO), and Foam Rejuvenating Toner (0.5% SA) daily for 12 weeks. No control group or reference treatment will be included.
Primary purpose:
Treatment
Trial design:
Single Group Assignment
Masking:
None (Open Label)
Allocation:
Not applicable
Primary outcomes:
Mean percent changes in inflammatory (IL), non-inflammatory (NIL), and total lesion (TL) counts from Baseline to each study visit
Timeframe: Baseline (Day 1) and Week 1, 2, 4, 8, 12
Number of participants with a minimum 2-grade improvement of Investigator’s Static Global Assessment (ISGA) from Baseline to each study visit
Timeframe: Baseline (Day 1) and Week 1, 2, 4, 8, 12
Number of participants with ISGA score of 0 (clear) or 1 (almost clear) at each study visit
Timeframe: Week 1, 2, 4, 8 and 12
Secondary outcomes:
Absolute change in IL, NIL, and TL count from Baseline to each study visit
Timeframe: Baseline (Day 1) and Week 1, 2, 4, 8, 12
Mean change in ISGA from Baseline to each study visit
Timeframe: Baseline (Day 1) and Week 1, 2, 4, 8, 12
Interventions:
Other: acne system - benzoyl peroxide 2.5%, Salicyclic Acid 0.5%
Enrollment:
125
Observational study model:
Not applicable
Primary completion date:
2011-15-12
Time perspective:
Not applicable
Clinical publications:
Jennifer Gwazdauskas, Leon Kircik, Lawrence Green, Victoria Butners. Phase IV MaxClarity efficacy, safety, and tolerability manuscript. J Drugs Dermatol. 2013;12(3):259-264.
Medical condition
Acne Vulgaris
Product
SKF63828, benzoyl peroxide, benzoyl peroxide/salicylic acid
Collaborators
GSK
Study date(s)
June 2011 to December 2011
Type
Interventional
Phase
Not applicable
Participation criteria
Sex
Female & Male
Age
12 - 35 years
Accepts healthy volunteers
No
- Capable of understanding and willing to provide signed and dated written voluntary informed consent (and any local or national authorization requirements) before any protocol-specific procedures are performed.
- Male or female ages 12 to 35 years, inclusive at time of consent.
- Female who is pregnant, trying to become pregnant, or breast feeding.
- History of lupus, dermatomyositis, rosacea, seborrheic dermatitis, beard folliculitis, polycystic ovary syndrome, hirsutism, or perioral dermatitis. (Subjects with Seborrheic dermatitis may be enrolled if the condition has been inactive for at least 1 year and/or it does not affect the face.)
Inclusion and exclusion criteria
Inclusion criteria:
- Capable of understanding and willing to provide signed and dated written voluntary informed consent (and any local or national authorization requirements) before any protocol-specific procedures are performed. -Male or female ages 12 to 35 years, inclusive at time of consent. -ISGA score of 3 or 4 at Baseline. -Lesion counts meeting all of the following criteria: A: A minimum of 25 but not more than 50 facial inflammatory lesions (papules and pustules), excluding nasal lesions. B: A minimum of 20 but not more than 100 facial non-inflammatory lesions (open and closed comedones), excluding nasal lesions. C: No more than 3 facial nodular lesions (<5mm), with no cystic lesions. -Ability and willingness to follow all study procedures, attend all scheduled visits, and successfully complete the study. -Negative urine pregnancy test for females of childbearing potential. -Sexually active females of childbearing potential participating in the study must agree to use a medically acceptable method of contraception while receiving protocol-assigned product.
Exclusion criteria:
- Female who is pregnant, trying to become pregnant, or breast feeding. -History of lupus, dermatomyositis, rosacea, seborrheic dermatitis, beard folliculitis, polycystic ovary syndrome, hirsutism, or perioral dermatitis. (Subjects with Seborrheic dermatitis may be enrolled if the condition has been inactive for at least 1 year and/or it does not affect the face.) -Use of topical antibiotics on the face within the past 2 weeks or of systemic antibiotics for acne treatment within the past 4 weeks. -Concurrent use of medications known to be photosensitizers (eg, thiazides, tetracyclines, fluoroquinolones, phenothiazines, and sulfonamides) because of the possibility of augmented photosensitivity. -Use of topical corticosteroids on the face within the past 2 weeks or systemic corticosteroids within the past 4 weeks. Use of inhaled, intra-articular, or intra-lesional steroids other than for facial acne is acceptable. -Use of systemic retinoids (eg, isotretinoin) within the past 6 months. -Treatment with estrogens, including oral, implanted, injected, and topical contraceptives, androgens, or anti-androgenic agents for 12 weeks or fewer immediately prior to study enrollment. Subjects that have been treated with estrogens, as described above, androgens, or anti-androgenic agents for more than 12 consecutive weeks prior to study enrollment are allowed to enroll as long as they do not expect to change the dose or drug, or to discontinue use during the study and it has not been indicated for the treatment of acne vulgaris. -Male with facial hair that could interfere with study assessments. -Use of topical anti-acne medications (eg, BPO, retinoids, azelaic acid, resorcinol, sulfur and derivatives, SA, alpha or beta hydroxy acids, antioxidants, anti-wrinkle, antimicrobials, glycolic acid, abradants) within the past 2 weeks. Use of superficial facial procedures, and natural/herbal products within the past 4 weeks. -Concomitant use of medications that are reported to exacerbate acne as these may impact efficacy assessments. -Facial procedure (eg, blue light, chemical or laser peel, microdermabrasion) performed by aesthetician, beautician, physician, nurse, or other practitioner within the past 8 weeks. -facial skin cancer diagnosis in preceding 12 months. -Require or desire excessive or prolonged exposure to ultraviolet light (eg, sunlight or tanning beds) during the study. -Dermatological disorder that in the opinion of the investigator may interfere with the accurate evaluation of the subject's facial appearance. -Any major illness within 4 weeks before study enrollment. -Previous use of the study products. -Use of any investigational drug or procedure within the past 4 weeks or currently participating in another clinical study. -Known hypersensitivity or previous allergic reaction to any of the active components of the study product. -Any other condition which, in the judgement of the investigator, would put the subject at unacceptable risk for participation in the study. -Current drug or alcohol abuse. (Drug screening is not required.) -Considered unable or unlikely to attend the necessary visits. -Employee of the investigator, clinical research organization, Stiefel, a GSK company, or GlaxoSmithKline (GSK) who is involved in the study, or an immediate family member (eg, partner, offspring, parents, siblings or sibling's offspring) of an employee who is involved in the study. -
Trial location(s)
Location
GSK Investigational Site
Belleville, New Jersey, United States, 07109
Status
Study Complete
Location
GSK Investigational Site
Louisville, Kentucky, United States, 40217
Status
Study Complete
Location
GSK Investigational Site
Fremont, California, United States, 94538
Status
Study Complete
Location
GSK Investigational Site
Montclair, New Jersey, United States, 07042
Status
Study Complete
Location
GSK Investigational Site
Stony Brook, New York, United States, 11790
Status
Study Complete
Location
GSK Investigational Site
High Point, North Carolina, United States, 27262
Status
Study Complete
Location
GSK Investigational Site
Rockville, Maryland, United States, 20850
Status
Study Complete
Location
GSK Investigational Site
Knoxville, Tennessee, United States, 37922
Status
Study Complete
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Completed
Actual primary completion date
2011-15-12
Actual study completion date
2011-15-12
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website